JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
83 hedge funds and large institutions have $365M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
9% more funds holding
Funds holding: 76 → 83 (+7)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $173K
Holders
83
Holding in Top 10
4
Calls
–
Puts
$173K
Top Buyers
| 1 | +$5.56M | |
| 2 | +$4.58M | |
| 3 | +$3.73M | |
| 4 |
Millennium Management
New York
|
+$2.37M |
| 5 |
JPMorgan Chase & Co
New York
|
+$1.54M |
Top Sellers
| 1 | -$8.21M | |
| 2 | -$2.81M | |
| 3 | -$2.02M | |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.87M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.79M |